Imatinib mesylate is a selective inhibitor of the bcr/abl, c-kit and PDGF receptor tyrosine kinases. Its ocular toxicity is little known with mild periorbital oedema being the most commonly reported side effect. We here describe our experience on ocular complications in imatinib treated Ph+ CML patients, which consisted of a wide spectrum of adverse effects ranging from periobital oedema to serious adverse events such as glaucoma.
Ocular side effects in chronic myeloid leukemia patients treated with imatinib / Breccia, M; Gentilini, Fabiana; Cannella, L; Latagliata, R; Carmosino, I; Frustaci, A; Alimena, Giuliana. - In: LEUKEMIA RESEARCH. - ISSN 0145-2126. - STAMPA. - 32:(2008), pp. 1022-1025. [10.1016/j.leukres.2007.10.016]
Ocular side effects in chronic myeloid leukemia patients treated with imatinib.
BRECCIA M;GENTILINI, FABIANA;ALIMENA, Giuliana
2008
Abstract
Imatinib mesylate is a selective inhibitor of the bcr/abl, c-kit and PDGF receptor tyrosine kinases. Its ocular toxicity is little known with mild periorbital oedema being the most commonly reported side effect. We here describe our experience on ocular complications in imatinib treated Ph+ CML patients, which consisted of a wide spectrum of adverse effects ranging from periobital oedema to serious adverse events such as glaucoma.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
